Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 505 Results

Page 7 of 51« First «...5 678 9...20 30 40...»Last »

April 30, 2025

DBV Technologies Reports First Quarter 2025 Financial Results

April 11, 2025

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

March 27, 2025

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin^® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

March 24, 2025

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin^® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results…

February 25, 2025

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

January 13, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 8, 2025

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

December 11, 2024

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin^® Peanut Patch in Toddlers 1 – 3 Years-Old

December 2, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

November 11, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

Page 7 of 51« First «...5 678 9...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top